Combined administration of testosterone plus an ornithine decarboxylase inhibitor as a selective prostate‐sparing anabolic therapy-Reference-Cited by-同舟云学术

Combined administration of testosterone plus an ornithine decarboxylase inhibitor as a selective prostate‐sparing anabolic therapy

Published:2013-12-04 Issue:2 Volume:13 Page:303-310
ISSN:1474-9718
Container-title:Aging Cell
language:en
Short-container-title:Aging Cell

Author:

Jasuja Ravi¹,Costello James C.²,Singh Rajan³,Gupta Vandana¹,Spina Catherine S.²⁴,Toraldo Gianluca¹,Jang Hyeran¹,Li Hu²,Serra Carlo¹,Guo Wen¹,Chauhan Pratibha¹,Narula Navjot S.¹,Guarneri Tyler¹,Ergun Ayla²,Travison Thomas G.¹,Collins James J.²⁴,Bhasin Shalender¹

Affiliation:

1. Research Program in Men's Health: Aging and Metabolism Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Anabolic Therapies Brigham and Women's Hospital Harvard Medical School 221 Longwood Avenue Boston MA 02115 USA

2. Howards Hughes Medical Institute Center for BioDynamics Boston University Boston MA 02115 USA

3. Division of Endocrinology and Metabolism Charles Drew University of Medicine and Science David Geffen School of Medicine at UCLA Los Angeles CA 90059 USA

4. Wyss Institute for Biologically Inspired Engineering Harvard University Boston MA 02215 USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Cell Biology,Aging

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/acel.12174

Reference33 articles.

1. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.

2. The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men